新冠疫情建议在泌尿外科实践中的适用性:来自意大利三大疫情热点地区的数据
该回顾性分析评估了2020年1月1日至4月28日共17周内意大利伦巴第大区三家最大公立医院(布雷西亚、贝加莫、米兰)的所有泌尿外科活动,采用Join-point回归识别趋势变化并计算平均每周百分比变化(AWPC)。2020年泌尿外科活动从第8-9周持续下降至第11-13周,AWPC范围为-41%至-29.9%(p<0.001)。按Stensland等初步推荐及欧洲泌尿外科学会指南优先级分层,约三分之一已实施的泌尿肿瘤手术属于可推迟治疗。作者结论认为,高优先级手术和治疗时机推荐需根据医院资源与局部发病率进行调整。
要点
- 2020年泌尿外科活动从第8-9周持续下降至第11-13周,平均每周百分比变化范围为-41%至-29.9%(p<0.001)。
- 疫情期间实施的泌尿肿瘤手术中,约三分之一属于按初步泌尿外科推荐可推迟的治疗。
- 对非肌层浸润性膀胱癌(NMIBC)中等/紧急优先级患者、阴茎癌和睾丸癌患者、上尿路尿路上皮癌(UTUC)和肾细胞癌(RCC)中等优先级患者,推荐适用性高。
- 对NMIBC低/高优先级、UTUC高优先级、前列腺癌中等/高优先级及RCC低优先级患者,推荐适用性低。
- 作者结论:高优先级手术和治疗时机推荐需根据医院资源和局部疫情进行调整。
适用人群与场景
- 2020年1月1日至4月28日共17周内,意大利伦巴第大区三家最大公立医院(布雷西亚、贝加莫、米兰)的所有泌尿外科活动。
研究设计与关键结果
- 研究类型:回顾性分析,纳入三家公立医院(布雷西亚、贝加莫、米兰)2020年1月1日至4月28日共17周的所有泌尿外科活动。
- 主要结果:2020年泌尿外科活动趋势从第8-9周持续下降至第11-13周,平均每周百分比变化(AWPC)范围为-41%至-29.9%(p<0.001)。
- 按Stensland等初步推荐分层,疫情期间实施的泌尿肿瘤手术中约三分之一属于可推迟的治疗。
- 推荐适用性高:NMIBC中等/紧急优先级患者、阴茎癌和睾丸癌患者、UTUC和RCC中等优先级患者。
- 推荐适用性低:NMIBC低/高优先级患者、UTUC高优先级患者、前列腺癌中等/高优先级患者、RCC低优先级患者。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,高优先级手术和治疗时机推荐需根据医院资源和局部疫情进行调整。
- 作者结论认为,专家提供的大流行推荐应根据医院能力和不同疫情水平进行定制。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Lombardy has been the first and one of the most affected European regions during the first and second waves of the novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]).
OBJECTIVE: To evaluate the impact of coronavirus disease 2019 (COVID-19) on all urologic activities over a 17-wk period in the three largest public hospitals in Lombardy located in the worst hit area in Italy, and to assess the applicability of the authorities' recommendations provided for reorganising urology practice.
DESIGN SETTING AND PARTICIPANTS: A retrospective analysis of all urologic activities performed at three major public hospitals in Lombardy (Brescia, Bergamo, and Milan), from January 1 to April 28, 2020, was performed.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Join-point regression was used to identify significant changes in trends for all urologic activities. Average weekly percentage changes (AWPCs) were estimated to summarise linear trends. Uro-oncologic surgeries performed during the pandemic were tabulated and stratified according to the first preliminary recommendations by Stensland et al (Stensland KD, Morgan TM, Moinzadeh A, et al. Considerations in the triage of urologic surgeries during the COVID-19 pandemic. Eur Urol 2020;77:663-6) and according to the level of priority recommended by European Association of Urology guidelines.
RESULTS AND LIMITATIONS: The trend for 2020 urologic activities decreased constantly from weeks 8-9 up to weeks 11-13 (AWPC range -41%, -29.9%; p < 0.001). One-third of uro-oncologic surgeries performed were treatments that could have been postponed, according to the preliminary urologic recommendations. High applicability to recommendations was observed for non-muscle-invasive bladder cancer (NMIBC) patients with intermediate/emergency level of priority, penile and testicular cancer patients, and upper tract urothelial cell carcinoma (UTUC) and renal cell carcinoma (RCC) patients with intermediate level of priority. Low applicability was observed for NMIBC patients with low/high level of priority, UTUC patients with high level of priority, prostate cancer patients with intermediate/high level of priority, and RCC patients with low level of priority.
CONCLUSIONS: During COVID-19, we found a reduction in all urologic activities. High-priority surgeries and timing of treatment recommended by the authorities require adaptation according to hospital resources and local incidence.
PATIENT SUMMARY: We assessed the urologic surgeries that were privileged during the first wave of coronavirus disease 2019 (COVID-19) in the three largest public hospitals in Lombardy, worst hit by the pandemic, to evaluate whether high-priority surgeries and timing of treatment recommended by the authorities are applicable. Pandemic recommendations provided by experts should be tailored according to hospital capacity and different levels of the pandemic.
参考来源
- Dell'Oglio P, Cacciamani GE, Muttin F, et al. Applicability of COVID-19 Pandemic Recommendations for Urology Practice: Data from Three Major Italian Hot Spots (BreBeMi). Eur Urol Open Sci. 2021. PMID: 33554150. doi:10.1016/j.euros.2021.01.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。